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Abstract 
 
Marketing partnerships between non-profit organisations (NPOs) and industry 
generally bring favourable results for both parties (Brønn and Vrioni 2001; 
Varadarajan and Menon 1988). However, there is some scepticism about corporate 
exploitation of such arrangements and growing concern in Australia and elsewhere 
about partnerships between the pharmaceutical industry and NPOs (Angell 2006; 
Moynihan and Cassels 2005) and the co-sponsorship of Disease Awareness 
Advertising (DAA). This paper reports the findings from a study of how Australian 
women respond to DAA with differing sponsors including their ability to identify, and 
their attitude toward, the sponsor. The results are of importance for health NPOs 
considering partnership with industry in an effort to promote awareness of a health 
condition. 
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Industry Partnerships for Health Nonprofits and Disease Awareness Advertising 
  
Introduction 
 
Consumer activism and economic growth over the past three decades have resulted in an 
increase in companies engaging in socially responsibility marketing activities including 
corporate sponsorship of charities and non-profit organisations (NPOs) as well ascause-
related marketing (Dibb et al. 2001; Kotler et al. 2003). Such conduct can benefit companies 
through enhanced corporate identity and stakeholder relations as well as improving brand 
awareness, brand image, and ultimately increasing profit (Smith 1994; Weber 2006). These 
alliances can also benefit NPOs through an increase in exposure and funds for their activities  
(Polonsky and Wood 2001; Varadarajan and Menon 1988). However, there has been 
increased scepticism from consumer and public health advocates regarding pharmaceutical 
company alliances with health NPOs (Angell 2006; Moynihan and Cassels 2005). 
 
Jacobson (2005) was critical of a range of United States health NPOs that appeared to be 
influenced by their relationships with (and funding received from) industry groups. It has
been suggested that such alliances can cause health NPOs to shield industry in times of crisis, 
and can turn the focus of the NPO toward medicinal treatments rather than behaviour change 
or prevention (Jacobson 2005; Moynihan and Cassels 2005). Moynihan et al (2005) describe 
that while many health NPOs work with the pharmaceutical industry to gain greater 
recognition for their particular cause, the company may be using the relationship to create 
stronger links between their product and the disease in an effort to increase market sh e. 
 
Disease Awareness Advertising (DAA) 
 
In Australia, where Direct to Consumer Advertising (DTCA) of prescription medicines is 
prohibited, pharmaceutical companies can still advertise directly to consumers about the 
disease or health condition for which they manufacture a product or treatment. This form of
promotion is called Disease Awareness Advertising (DAA) and is permissible provided there 
is no mention of a specific product or brand and consumers are encouraged to consult their 
doctor for further advice (Medicines Australia 2006). 
 
There is debate regarding the potential positive and negative effects of pharmaceutical 
company sponsored DAA. There is concern that DAA can inflate the perceived prevalenc  of 
disease and create fear and anxiety which potentially leads to unnecessary visits to health 
practitioners (Mintzes 2006). There is also concern that consumers will not recognize the 
commercial intent of DAA and perceive it to be form of community service announcement, 
and therefore will be more vulnerable to its persuasive effect (Mackenzie et al. 2007). There is 
a counter argument, however, that DAA serves a valuable health education function and helps 
consumers identify symptoms and be more proactive in seeking treatment (Auton 2007).  
 
In some instances, pharmaceutical companies co-sponsor DAA with health NPOs. A recent 
Australian example is an advertising campaign to promote bone density testing by 
Osteoporosis Australia with Merck Sharp & Dohme who produce Fosomax, a product to treat 
osteoporosis by increasing bone density. There have been some controversial case  of o-
sponsored DAA which have brought about a degree of consumer cynicism (Hall and Jones 
2006). For example, there was criticism of the National Asthma Council of Australia when it 
conducted a public awareness campaign using a dragon spokes-character ‘Puff’, particularly 
as this same character had been (and is still being) used to market GlaxoSmithKline’s asthma 
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treatment product (Seretide) to general practitioners (Hughes and Minchin 2003). Further 
examples can be found on the Crikey Register of Influence (Crikey 2009).  
 
From an industry viewpoint, there is evidence of the effectiveness of DAA. Studies in the US 
and the Netherlands have found that pharmaceutical sponsored DAA resulted in increased 
prescriptions and market share for prescription products (Basara 1996; t'Jong, Stricker and 
Sturkenboom 2004). There is a dearth of research regarding the effectiveness of  
pharmaceutical and NPO co-sponsored DAA. Only one, somewhat dated study was located, 
where an NPO partnered with a food manufacturer in an effort to reduce bowel cancer. 
Hammond (1987) conducted the study with 264 volunteers in the US, showing print, radio 
and television advertisements with a health promotion message (to increase dietary fibre) 
where the sponsor was manipulated. The sponsor varied between a NPO (the National Cancer 
Institute), a well-known food manufacturer (Kellogg’s), and a combination of the two. She 
found that the NPO and industry combination sponsor or the NPO sponsor alone, were rated 
significantly higher by participants than industry sponsor alone. However there was no 
significant difference between the NPO alone and the combination sponsor. In a commentary 
on the ensuing advertising campaign, Freimuth (1988) reported improvements in consumer 
health knowledge and behaviour, as well as an increased market share for Kellogg’s.  
 
Source credibility 
 
There is considerable evidence that the use of a highly credible source within an 
advertisement will increase persuasion (Petty and Cacioppo 1986; Pornpitakpan 2004). 
Pornpitakpan (2004) identified expertise and trustworthiness as the most commonly identified 
dimensions of source credibility. Expertise refers to the capacity of the source t  provide 
information on the topic or product, while trustworthiness refers to the audience perception 
that the source truly believes what it is claiming. Two forms of source credibility can be 
influential in advertising: that of the endorser or presenter (such as a celebrity); and that of the 
company or organisation identified with the product (Lafferty, Goldsmith and Newell 2002; 
Pornpitakpan 2004). This latter form of source credibility is commonly referred to as 
corporate credibility, and also includes the dimensions of expertise and trustworthiness 
(Goldsmith, Lafferty and Newell 2000). 
 
Studies have demonstrated corporate credibility can impact on attitudes toward the 
advertisement, attitudes towards the brand, as well as purchase intention (Goldsmith et al. 
2000; Lafferty et al. 2002).  In the Hammond (1987) study previously described, while there 
was no significant relationship found between corporate credibility and message acceptan e, 
corporate credibility did affect behaviour intention.  
 
The current study 
 
It is likely that co-sponsored DAA will increase in the future, particularly in countries such as 
Australia where DTCA of prescription medicine is not permitted. For the pharmaceutical 
industry, DAA is one of the few permitted methods for communicating directly with 
consumers, and its capacity to increase prescriptions and market share for pharmaceutical 
products has been demonstrated (t'Jong et al. 2004). Partnerships with NPOs are desirabl  to 
bolster the source credibility and persuasiveness of advertisements. From the viewpoint of the 
NPO, increasing competition from other health-related causes and the prohibitive cost of 
mass-media advertising leaves them in need of industry resources to promote awareness of 
their particular disease or health condition. However, as previously described, ther  are 
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increasing concerns regarding alliances between health NPOs and the pharmaceutical industry 
and some examples of co-sponsored DAA that have evoked consumer scepticism (Crikey 
2009). The current study aimed to determine whether it is beneficial for health NPOs to 
partner with the pharmaceutical industry in sponsorship of DAA. In particular, how 
Australian women perceived advertisements for two health conditions, including their ability 
to identify, and their attitude toward, the sponsor.  
 
 
Method 
 
Older women were approached in a commercial shopping centre in a metropolitan area in 
NSW and shown advertisements for two relatively unknown health conditions: fibromyalgia 
and osteopenia. Advertisements were developed using marketing-communication principles 
(Rossiter and Bellman 2005; Rossiter and Percy 1997) but also to reflect current DAA in 
Australian magazines. The health conditions were selected as the authors could find no 
evidence of mass media education or past pharmaceutical promotions about these conditions 
that target consumers in Australia. 
 
Consenting participants were randomly assigned an advertisement using a computer random 
allocation resource (Urbaniak and Plous 2008). For each health condition, there were three 
potential sponsor types: pharmaceutical company, NPO and a combination of pharmaceutical 
company and NPO. Each participant viewed and responded to two advertisements (with the 
same sponsor type). For example, if a participant was randomly assigned the co-sponsored 
advertisement for fibromyalgia, they would subsequently be shown the co-sponsored 
advertisement for osteopenia. Corporate branding of the sponsor(s) was clearly visible at the 
bottom of each advertisement. 
 
The advertisement questionnaire was developed based on previous questionnaires to 
determine consumer responses to DTCA and DAA (Hall and Jones 2008; Hoek, Gendall and 
Calfee 2004). Participants were asked who they thought the advertiser was and repo ed to a 
series of bipolar adjective scales, based on instruments used in relevant studies (Lafferty et al. 
2002; Newell and Goldsmith 2001). Additional questions were developed to capture 
demographic information of participants. 
 
Results 
 
A total of 185 women aged between 48 and 85 years (median age of 64 years), completed 356 
advertisement questionnaires. According to Australian Bureau of Statistics 2006 census data, 
women in this age group account for 42.5% of adult women. Similar to census data, sixty nine 
percent of participants were born in Australia, but 12% were born in the United Kingdom 
which is higher than census data. Ninety three percent of participants spoke English at home 
and approximately half had achieved a Year 12 or higher education level.  
 
A total of 178 advertisements were completed for each health condition, with between 116 
and 120 in each sponsor manipulation (across both health conditions). While only 36% 
reported that they or someone they knew well had suffered from fibromyalgia, 63% reported 
that they or someone they knew well had suffered from osteopenia. On a 6-point scale (1= 
difficult and 6 = easy) the mean rating of understanding for the advertisements was 5.46.  
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When asked who they thought the advertiser was, written responses were categorised into five 
generic categories (nominated sponsor category) and compared with the actual sponsor on the 
advertisement allocated to the participant. Overall, only 51% correctly identif ed the category 
of sponsor. The most nominated category was pharmaceutical company (47%), followed by 
NPO (31%) followed by government/research/medical (G/R/M) (8%). Table 1 shows the 
nominated sponsor category by actual sponsor type allocated. Participants viewing the 
pharmaceutical sponsor were most likely to correctly identify that category (83% p=.000), 
followed by those viewing the NPO sponsor where 66% correctly identified that category. 
Participants viewing the combination sponsor were more likely to nominate pharmaceutic l 
company (49%) or NPO (21%) than to correctly identify the combination sponsor (11%). 
 
Table 1: Percentage of sponsor type vs. nominated sponsor category  
  
Sponsor type Nominated sponsor category 
 Pharmaceutical NPO Combination G/R/M Unknown Other 
Pharmaceutical  83% 6% 0% 2% 4% 5% 
NPO 12% 66% 1% 13% 4% 5% 
Combination 49% 21% 11% 8% 4% 8% 
 
A score was created for attitude toward the sponsor (sp nsor score), which included 
responses to bipolar adjective scales for trustworthiness, expertise, reliability, honesty and 
believability of the advertiser or sponsor. Item-to-total correlations weregr ater than .805 and 
inter-item correlations were between .560 and .853. Principal Components Analysis was 
performed with one component extracted with an eigenvalue greater than one. All items 
loaded with values greater than .60. Cronbach’s alpha for the 5 item scale was .933. While 
sponsor scores for all nominated categories were high (see Table 2) a comparis n of mean 
scores for the nominated sponsor category shows that NPO sponsors were rated significantly 
higher than pharmaceutical sponsors (p=.000). Comparisons could not be made with other 
categories due to sample size limitations. 
 
Table 2 Mean sponsor score for nominated sponsor category 
  
Nominated Sponsor Category Mean N Std. Deviation 
Pharmaceutical  4.2073 137 1.13641 
NPO 5.1556 90 .82912 
Combination 4.3846 13 1.33532 
Government/research/medical 4.7333 21 .85167 
Unknown 4.8000 6 1.10995 
Other 4.9375 16 1.02168 
Total 4.6099 283 1.10840 
 
Multiple regression was performed with sponsor score as the dependent variable and 
condition type, nominated sponsor category (reduced to pharmaceutical or NPO sponsor by 
replacing other nominated categories as missing values), age, education level and personal 
experience (if they or someone they knew well had suffered from the advertised health 
condition) as the independent variables. The combination of the five independent variables 
significantly predicted sponsor score (F degrees of freedom = 15.832, p<.001) and explained 
27% of the variation of sponsor score (adjusted R2=.266). The results demonstrate that: 
increased age was independently associated with sponsor score (t = 2.642, p = .009); 
nominated sponsor category was the strongest independent predictor with NPO sponsors 
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predicting higher scores (t = 5.780, p = .001); personal experience of the health condition 
independently predicted higher sponsor scores (t=-2.317, p=.021); and lower education level 
predicted higher sponsor scores (t=-2.562, p=.011). The advertised condition type (osteopenia 
or fibromyalgia) did not independently predict sponsor scores (t = .014, p=.989). 
 
 
Discussion and Conclusion 
 
The results show that only half of the participants were able to correctly identify the sponsor 
of the DAA despite clear corporate branding at the bottom of each advertisement. Almost half 
of the participants perceived the advertiser to be a pharmaceutical company regardless of the 
corporate brand displayed on the advertisement.  
 
In considering attitudes towards the sponsor, older, less educated women and those with 
personal experience of the condition were more likely to rate sponsors of the DAA more 
favourably. It is likely that these groups are also potentially more influenced by the persuasive 
effects of DAA as this has been found to be the case for DTCA (Christensen, Ascione and 
Bagozzi 1997). Participants who perceived the advertiser to be a pharmaceutical comp ny 
were more likely to rate this sponsor less favourably than those who perceived the advertiser 
to be a NPO. These results reinforce findings that NPO and government sources are g nerally 
perceived by consumers to be more credible than commercial sources (Hayley 1996). Almost 
half of the participants receiving co-sponsored advertisements perceived the advertiser to be a 
pharmaceutical company, and less than a quarter perceived the advertiser to be a NPO, 
suggesting that co-sponsored arrangements may also be viewed less favourably.  
 
While further research is required to determine consumer perceptions of sponsors of DAA in 
different mediums, and how this effects their behavioural intentions, the results suggest that 
consumers would feel more favourably toward DAA sponsored by NPOs alone The growing 
concern about pharmaceutical involvement with health NPOs, and consumer cynicism 
surrounding cases of co-sponsored DAA may also detract from potential partnerships with 
industry in promoting awareness about disease. NPOs however may benefit from increasing 
the exposure of their own corporate branding in DAA, and ensuring that their advertisem nt  
are clearly differentiated from those sponsored by pharmaceutical companies. 
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